🚀 Exciting News from ACROBiosystems! 🚀 We are thrilled to unveil our new state-of-the-art GMP facility, purpose-built to tackle the unique challenges of the cell and gene therapy (CGT) sector with our Resilient Supply brand—your assurance of flexible, high-quality solutions coupled with steadfast global supply and comprehensive regulatory support. Resilient Highlights: - Robust Global Supply: Multi-point distribution ensures continuous availability. - Regulatory Excellence: Compliant with EU, US, and China regulations for unparalleled reliability. - Advanced GMP Quality Management: Upholds superior standards - Cost-effective outcomes. From immunotherapy and stem cells to organoids, we offer innovative products like: - CelThera™ GMP T Cell Expansion Medium - iPSC Culture Solution Laminin 511 Mix & Go ECM Protein - GMP-grade DLL4 Protein for feeder-free NK cell differentiation - Regulatory-compliant rapid test kits, fully validated, significantly shortening cell therapy drug release cycles Our Resilient Supply products and solutions cover the entire drug development process from early discovery, process development and production, characterization and quality control, and safety testing, to clinical research. #CGT #CellTherapy #GeneTherapy #GMP #Biotechnology #Innovation #ACROBiosystems
ACROBiosystems
Biotechnology Research
Newark, Delaware 25,915 followers
Where Proteins and Innovation Advance Biomedicine
About us
ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.
- Website
-
http://www.acrobiosystems.com
External link for ACROBiosystems
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Newark, Delaware
- Type
- Public Company
- Founded
- 2010
- Specialties
- Proprietary HEK293 expression platform, In-house developed enzymatic and chemical biotin labeling technique, covid-19 antigens and antibodies, CAR-T, Reagents for COVID-19 vaccine development and evaluation, SARS-CoV-2 Related Kit Products, Targets for Antibody-Drug Conjugates, Hot target for bispecific antibody, CD3, Bispecific Antibody, Sars-cov-2 mutants, ADCs, Sars-cov-2 kits, Targets for CAR-T Cell Therapy, Multi-pass Transmembrane Proteins and Technology Platforms, Immune Checkpoint, Cytokine, BsAb targets, Fc Receptors, MABSOL Biotinylated Protein, Enzymes, Anti-idiotypic Antibodies, Cell Gene Therapy, and GMP grade Cytokines
Locations
Employees at ACROBiosystems
Updates
-
#MeetwithACRO [ACRO Event - Taiwan] One day left at #BIOAsia. Come with #ACROLlama to our booth at #M1033! Meet our APAC team and learn about how ACRO can support your research from #discoverystage to #clinicaltrials and discuss potential partnerships! #BIOAsiaTaiwan #biotech #reagents #recombinantproteins #GMP #partnerships
-
#ACROHighlights [Featured Product] 🚀 Unlock the Future of Autoimmune Disease Therapies 🚀 Cytokines are key players in autoimmune diseases (AID). Targeting these inflammatory mediators opens doors to more effective treatments. Dive into our latest article exploring the link between cytokines and conditions like ankylosing spondylitis, psoriatic arthritis, and systemic sclerosis. Discover our comprehensive range of recombinant cytokines and receptors, designed to propel your autoimmune drug development efforts. 🔗 https://smpl.is/9ezwo #Innovation #Biotech #DrugDevelopment #Healthcare #LifeSciences
-
-
#MeetwithACRO [ACRO Event - Taiwan] Day 1 at #BIOAsia! Come to our booth at #M1033 to meet our APAC team and learn more about our products and discuss potential partnerships! #BIOAsiaTaiwan #biotech #recombinantproteins #partnerships
-
-
#ACROHighlights [Featured Product] 🚀CD151: A Pivotal Tumor Marker and Therapeutic Target CD151, a tetraspanin protein, plays a crucial role in cancer progression. Widely expressed, it interacts with integrins to regulate tumor cell adhesion, migration, signaling, and angiogenesis. CD151's expression levels correlate with cancer grade, stage, and prognosis, making it an invaluable diagnostic marker and a prime therapeutic target. ACROBiosystems offers high-quality, full-length CD151 proteins (Gly 2-Tyr 253) with FLAG tags to advance your research and development of CD151-targeted therapies. 🔗https://lnkd.in/ghbrWZYk Join us in pioneering the future of cancer treatment! 💡 #OncologyResearch #CancerTherapy #BiotechInnovation
-
-
#ACROHighlights [Featured Product] 🔬Multiple Companies Target the Leading Non-Fatal Skin Disease in Treatment Burden 📅 June 11: BioCure announced that Bosakitug, a highly effective anti-TSLP monoclonal antibody, achieved remarkable Phase 2 clinical trial results. 🌟 94% of patients experienced complete or near-complete clearance of skin lesions. 📅 June 13: The Chinese National Medical Products Administration (NMPA) approved Pfizer's innovative drugs, PF-07264660 (targeting IL-4/IL-13/IL-33) and PF-07275315 (targeting IL-4/IL-13/TSLP), for clinical trials in China to treat moderate to severe atopic dermatitis in adults. To support the development of TSLP/TSLPR/IL-17R alpha pathway-related antibody drugs and agonists, we have developed a comprehensive range of TSLP tools, including multiple species and tags recombinant proteins. These tools are instrumental in advancing treatments for asthma and atopic dermatitis. 🔗https://lnkd.in/guYSJWjk Together, we're striving towards better treatments and brighter futures! 💡 #Biotech #AtopicDermatitis #ClinicalTrials #InnovationsInHealth
-
-
#ACROConnect [ACRO Workshop – Philadelphia, Pennsylvania] 🎉We had a fantastic workshop last week! A heartfelt thank you to everyone who joined us and a big shoutout to our amazing ACRO team Rachel Daniels Zoe Putman Noah Jacobs-Rebhun for making this happen. Special thanks to our incredible speakers Kaiyuan Jiang Trang Vu, and Rajneesh Jha, Ph.D. for the insightful talks! It was thrilling to see everyone enjoying the workshop, delicious food, and the delightful presence of ACRO’s adorable Golden llamas. The energy in the room was incredible, and we even ran out of seats toward the end! The first roundtable discussion was buzzing with great questions, and it was wonderful to see so many new connections being made during the networking session. We are proud to provide this platform to enhance the greater Philadelphia Biotech community. Our next Cell and Gene Therapy workshop will be in South San Francisco, CA, on August 15, and the next Antibody Drug Discovery and Development workshop will be at Cambridge, MA, on August 23. Stay tuned for more details, and we can't wait to connect with you at our upcoming workshops! #cell #gene #therapy #CGT #celltherapy #genetherapy #cellandgenetherapy #celltherapymanufacturing #celltherapyoptimization #research #networking #ACROLlama #freeworkshop #scientists #researcher #biopharma #biotechnology #biotech #bioindustry #industryinsights #CareerGrowth #philadelphia #events
-
-
-
-
-
1
-
-
#ACROHighlights [Featured Product] 🌟 Streamline Your Organoid Differentiation Process! 🌟 Unlock the power of iPSC-derived organoids, a game-changer in replacing animal models and advancing target discovery and drug development. Our detailed protocol videos guide you through every step of the organoid differentiation process—from initial cell culture to mature organoid formation and identification. 🎥 Watch now and elevate your research: https://smpl.is/9ehco #Biotech #StemCells #Organoids #DrugDevelopment #ResearchInnovation
-
-
#ACROHighlights [Featured Product] Introducing the Human FcRn Binding Kit: Advanced TR-FRET Technology for Superior Antibody Screening! 🔬 In the dynamic field of antibody-drug development, the interaction between IgG and FcRn (neonatal Fc receptor) is crucial. Enhance your research precision with our Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology. 🚀 Our Human FcRn Binding Kit is designed to streamline and optimize your antibody screening process, ensuring faster and more efficient results. ✨ Why Choose Our Kit? - High Precision: Achieve unparalleled accuracy in your assays. - Efficiency: Accelerate your screening and optimization processes. - Reliability: Trusted technology for dependable results. 🎁 Limited Offer: Request your free sample today and take your research to the next level! https://smpl.is/9ecdb #Biotech #Innovation #AntibodyScreening #TRFRET #DrugDevelopment #ScientificResearch
-
-
#ACROHighlights [Featured Product] A New Era for Alzheimer's Treatments! 🧠✨ The FDA has approved Eli Lilly's Kisunla (donanemab) for early-stage Alzheimer's disease (AD). 🌟 Donanemab targets the N3pG subtype of β-amyloid (Aβ), effectively clearing amyloid plaques in the brain. Key Results: 35% slower cognitive decline over 18 months 📉 39% reduced risk of late-stage AD 🛡️ 61% plaque reduction at 6 months 80% plaque reduction at 12 months 84% plaque reduction at 18 months This breakthrough offers new hope for AD treatment! 🌟 At Aneuro, we're driving AD drug development with essential target proteins like Aβ, Tau, TREM2, and APOE. 🧬 Our innovative solutions include Tau PFFs and Cerebral organoid models, helping to create robust AD disease models. Together, we're pioneering the future of Alzheimer's treatment. 🌟🔬 🔗https://lnkd.in/gP4ViZ8n #Alzheimers #Biotech #Innovation #Healthcare #FDAApproval #Aneuro
-